News & Updates
Filter by Specialty:
Neoadjuvant olaparib feasible in BRCA-mutated ovarian cancer
Neoadjuvant treatment with the PARP* inhibitor olaparib yielded encouraging outcomes in patients with BRCA-mutated ovarian cancer, with all participants completing two cycles of therapy followed by surgery in the NOW trial presented at SGO 2023.
Neoadjuvant olaparib feasible in BRCA-mutated ovarian cancer
23 May 2023
In-utero exposure to poor air quality a risk factor for childhood ADHD
Children born to mothers who were exposed to polluted air while pregnant are at increased risk of childhood attention-deficit hyperactivity disorder (ADHD), according to a study presented at PAS 2023.
In-utero exposure to poor air quality a risk factor for childhood ADHD
20 May 2023
Hypertension risk postpregnancy high among women with heart disease
Women with heart disease are at increased risk of developing hypertension in the decades after pregnancy compared with those without heart disease, as reported in a retrospective study.
Hypertension risk postpregnancy high among women with heart disease
16 May 2023
Toripalimab plus bevacizumab, SoC demonstrates promising efficacy for cervical cancer
Preliminary results of a single-arm, open-label, phase II trial demonstrated the efficacy of a combination regimen comprising toripalimab, bevacizumab, and platinum-based chemotherapy for women with refractory, recurrent, or metastatic cervical cancer.
